PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
From:
Antivir Ther. Author manuscript; available in PMC Jan 1, 2011.
Published in final edited form as:
Antivir Ther. 2010; 15(4): 571–577.
doi: 10.3851/IMP1557

Table 4

Association of HIV Status, NRTI Use, and Mean Corpuscular Volume with Percent Change in Log Hemoglobin A1c Values from Multivariate Linear Regression Models

Model 1Model 2a
Percent Changeb95% CIP-valuePercent Changeb95% CIP-value
Log plasma glucose (mg/dL)56.9452.18, 61.85<0.00153.9749.23, 58.85<0.001
HIV Status/Specific antiretroviral use:
 HIV-uninfectedreferentreferent
 HIV-infected not taking ZDV or 3TC-0.34-1.71, 1.050.631-0.03-1.35, 1.310.964
 HIV- infected taking 3TC but not ZDV-1.53-3.06, 0.030.055-0.07-1.67, 1.550.934
 HIV-infected taking ZDV with or without 3TC-2.40-4.01, -0.770.0041.26-0.61, 3.160.187
Mean corpuscular volume (per 10 fL)-2.10-2.70, -1.60<0.001
aModel 2 is identical to Model 1 except for inclusion of mean corpuscular volume as a covariate
bReflects the percentage change on a multiplicative scale relative to the referent group, obtained as 100(expβ-1) where β is the regression coefficient (or corresponding lower or upper confidence limit for this coefficient) using log-transformed hemoglobin A1c as the outcome

Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; 3TC, lamivudine; ZDV, zidovudine